Influence of an "opt-out" test strategy and patient factors on human immunodeficiency virus screening in pregnancy

被引:23
作者
Yudin, Mark H. [1 ]
Moravac, Catherine [1 ]
Shah, Rajiv R. [1 ]
机构
[1] Univ Toronto, Dept Obstet & Gynecol, St Michaels Hosp, Toronto, ON M5B 1W8, Canada
关键词
D O I
10.1097/01.AOG.0000267497.39041.06
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To estimate both human immunodeficiency virus (HIV) testing acceptance rates in pregnancy using an opt-out policy and patient characteristics influencing acceptance. METHODS: At the first prenatal visit, HIV testing was offered using an opt-out approach. Reasons for refusing testing were explored. Demographic information was collected on all study subjects. RESULTS: In the prospective portion of the study, 1,140 of 1,233 women (92.5%) accepted testing. Race was predictive of accepting HIV testing, with Asian women significantly less likely (odds ratio [OR] 0.4, 95% confidence interval [CI] 0.3-0.6; P<.001) and Hispanic women significantly more likely (OR 6.9; 95% CI 2.2-22.0; P=.001) to be tested. Although English as a first language, country of birth, and insurance status were not significantly associated with acceptance, women who were fluent in English were more likely to be tested (OR 2.0; 95% CI 1.2-3.3; P=.01). Our testing rates were significantly higher than the provincial average. CONCLUSION: Using an opt-out strategy, HIV testing rates in our clinic were significantly higher than the provincial average. Rates were influenced by race and fluency in English.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 16 条
[1]  
ACOG Committee on Obstetric Practice, 2004, Obstet Gynecol, V104, P1119
[2]   The effectiveness of a verbal opt-out system for human immunodeficiency virus screening during pregnancy [J].
Breese, P ;
Burman, W ;
Shlay, J ;
Guinn, D .
OBSTETRICS AND GYNECOLOGY, 2004, 104 (01) :134-137
[3]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1013
[4]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[5]  
Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
[6]  
*CTR DIS CONTR PRE, 2001, MMWR RECOMM REP, V50, P63
[7]   Organizational predictors of prenatal HIV counseling and testing [J].
Ethier, KA ;
Fox-Tierney, R ;
Nicholas, WC ;
Salisbury, KM ;
Ickovics, JR .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (09) :1448-1451
[8]  
Jayaraman GC, 2003, CAN MED ASSOC J, V168, P679
[9]   Trends in HIV testing among pregnant women: United States, 1994-1999 [J].
Lansky, A ;
Jones, JL ;
Frey, RL ;
Lindegren, ML .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2001, 91 (08) :1291-1293
[10]  
LINDSAY MK, 1991, OBSTET GYNECOL, V78, P678